Juvenile idiopathic arthritis

Lancet. 2007 Mar 3;369(9563):767-778. doi: 10.1016/S0140-6736(07)60363-8.


Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years of age. This term encompasses several disease categories, each of which has distinct methods of presentation, clinical signs, and symptoms, and, in some cases, genetic background. The cause of disease is still poorly understood but seems to be related to both genetic and environmental factors, which result in the heterogeneity of the illness. Although none of the available drugs has a curative potential, prognosis has greatly improved as a result of substantial progresses in disease management. The most important new development has been the introduction of drugs such as anticytokine agents, which constitute a valuable treatment option for patients who are resistant to conventional antirheumatic agents. Further insights into the disease pathogenesis and treatment will be provided by the continuous advances in understanding of the mechanisms connected to the immune response and inflammatory process, and by the development of new drugs that are able to inhibit selectively single molecules or pathways.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Arthritis, Juvenile / classification
  • Arthritis, Juvenile / diagnosis*
  • Arthritis, Juvenile / genetics
  • Arthritis, Juvenile / immunology
  • Arthritis, Juvenile / therapy*
  • Child
  • Child, Preschool
  • Chronic Disease
  • Diagnosis, Differential
  • Disease Progression
  • Female
  • HLA Antigens / genetics
  • Humans
  • Infant
  • Inflammation / immunology
  • Injections, Intra-Articular
  • Male
  • Physical Therapy Modalities
  • Prognosis
  • Steroids / administration & dosage
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • HLA Antigens
  • Steroids